ArticleBiomarkers in medicine2025
The monocyte-to-HDL-cholesterol ratio predicts new-onset atrial fibrillation in patients with acute STEMI.
Article in Biomarkers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Monocyte-to-HDL ratio predicts 30-day mortality in middle-aged and elderly patients with HBV-related decompensated cirrhosis.BMC infectious diseases · 2026Article
- Predictive value of the monocyte-to-high-density lipoprotein cholesterol ratio in atrial fibrillation: a meta-analysis.Frontiers in cardiovascular medicine · 2026Review
- The association between the monocyte-to-HDL cholesterol ratio and coronary collateral circulation in patients with chronic total occlusion.BMC cardiovascular disorders · 2025Article
- Monocyte-to-HDL-cholesterol ratio and 1-year mortality in critically ill coronary heart disease: A MIMIC cohort study.Science progressArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveNewly diagnosed AF (NOAF) associated with acute STEMI holds significant relevance in clinical practice. This study seeks to assess the role of the monocyte to HDL-C ratio (MHR) in predicting NOAF in these patients.
methodsBetween July 2017 and May 2018, 663 patients who underwent primary PCI for STEMI were retrospectively analyzed. NOAF was identified in 34 patients (5.1%), and this group was compared with those without AF.
resultsThe NOAF group experienced a longer hospitalization duration and a higher mortality rate (11.8 vs. 4.3%,
conclusionThe present study revealed that increased MHR robust indicator for NOAF in STEMI patients and can be easily assessed in clinical practice. Incorporating MHR alongside established traditional risk factors may enhance the identification of patients at risk for AF in those with STEMI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.